ReviewJournal of clinical and experimental hepatology
Vaccination in Chronic Liver Disease: An Update.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.Clinical and molecular hepatology · 2022Pooled it
- Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026Review
- Hepatitis B Virus, Pneumococcal, Diphtheria, and Tetanus Vaccination Responses in Compensated Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Immunodeficiencies in Adults: Key Considerations for Diagnosis and Management.Clinical reviews in allergy & immunology · 2025Review
- Recommended vaccinations for patients with chronic liver diseases.Clinical and experimental hepatology · 2025Review
- Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer.Cancers · 2025Article
- Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system.Frontiers in public health · 2025Article
- Pneumococcal sternoclavicular septic arthritis: A rare manifestation of invasive pneumococcal disease.IDCases · 2025Article
- Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide.World journal of hepatology · 2024Review
- Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients.BMC gastroenterology · 2024Article
- Cellular immune response to a single dose of live attenuated hepatitis a virus vaccine in obese children and adolescents.Heliyon · 2024Article
- Accelerated aging of skeletal muscle and the immune system in patients with chronic liver disease.Experimental & molecular medicine · 2024Article
- Review
- A Comprehensive Review of Hepatitis B Vaccine Nonresponse and Associated Risk Factors.Vaccines · 2024Review
- Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota.Vaccines · 2024Review
- Type 1 interferon auto-antibodies are elevated in patients with decompensated liver cirrhosis.Clinical and experimental immunology · 2024Article
- Tiza-BMJ open · 2023Article
- Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients.Vaccines · 2023Article
- Review
- Durability of Antibody Response Six Months After Two-Dose SARS-CoV-2 mRNA Vaccination in Patients with Cirrhosis.Gastro hep advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic liver disease (CLD) with or without cirrhosis remain at risk of developing hepatic decompensation when infected with viral or bacterial pathogens. The Advisory Committee on Immunization Practices (ACIP) currently recommends vaccination in CLD against hepatitis A virus (HAV), hepatitis B virus (HBV), influenza, pneumococcus, herpes zoster, tetanus, diphtheria, pertussis, and SARS-CoV-2. Inactivated vaccines are preferred over live attenuated ones, especially in transplant recipients where live vaccines are contraindicated. As the severity of the liver disease progresses, vaccine efficacy declines, and therefore, vaccines should be ideally administered early in the disease course for optimal immune response. Despite the strong recommendations, overall vaccination coverage in CLD remains poor; however, it is encouraging to note that in recent years coverage against influenza and pneumococcus has shown some improvement. Inadequate access to healthcare, lack of information on vaccine safety, poor financial reimbursement for healthcare providers, and vaccine misinformation are often responsible for low immunization rates. This review summarizes the impact of vaccine-preventable illness in those with CLD, updated vaccine guidelines, seroconversion rates in the vaccinated, and barriers faced by healthcare professionals in immunizing those with liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.